AUSTIN, Texas, June 1, 2011 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX), today announced it has signed a global sales and distribution agreement with Life Technologies Corporation (NASDAQ: LIFE) for its award-winning MAGPIX multiplexing instrument for analysis of proteins for research use. Launched in July 2010, MAGPIX is a compact multiplex analyzer that can quickly, accurately and reproducibly detect 50 different analytes simultaneously on a single sample, including proteins and nucleic acids.
“We are very pleased to have Life Technologies as a global distribution partner for MAGPIX. This new, highly innovative instrument is an important advancement in Luminex’s goal to create multiplexing solutions for a range of applications and for laboratories of all sizes,” said Michael F. Pintek, senior vice president of operations for Luminex. “With its global scope, Life Technologies helps ensure that this advanced multiplexing solution reaches the right scientists and researchers. This partnership will help accelerate science and improve the efficiency of disease-related research around the world.”
Providing nearly 5,000 data points in under an hour, MAGPIX was designed to meet the needs of laboratories, academic researchers and scientists who, until now, have not been able to take advantage of the power of multiplexing because of resource and space limitations. Based on Luminex’s xMAP® Technology, the easy-to-use MAGPIX instrument is compact - comparable in size to a desktop computer - making it attractive to a broad array of laboratories and institutions. Due to its adaptability, the instrument can advance research across many disease states by bringing many types of multiplexing applications to scientists. Additionally, MAGPIX allows users of legacy approaches, such as ELISA and Western Blot, to enjoy the advantages of xMAP Technology for single analyte or multiplexed testing.
“Life Technologies is pleased to be a partner in the global distribution of the MAGPIX instrument,” said Peter Dansky, president of Molecular and Cell Biology at Life Technologies. “MAGPIX represents a unique platform through which Life Technologies can make its cutting-edge antibody content accessible for a broad range of protein quantitation needs in basic and clinical research.”
MAGPIX saves vital time in the laboratory, produces faster, accurate, reproducible results and requires less sample input than existing legacy technologies such as ELISA and Western blot. Like other Luminex instruments, MAGPIX is versatile and flexible and can be used to analyze both nucleic acids and proteins, making it applicable in many research settings. MAGPIX is easy to install out of the box and weighs less than 40 lbs., approximately 18 kg, making it simple and affordable to ship and deploy anywhere in the world.
MAGPIX was awarded a prestigious 2011 Medical Design Excellence Award for Innovative Design and Contribution and recently received CE IVD mark in Europe.
MAGPIX is for research use only in the United States. Not for use in diagnostic procedures.
For more information on MAGPIX, call 512.219.8020, or visit www.luminexcorp.com/magpix
About Luminex Corporation
Luminex Corporation (NASDAQ: LMNX) develops, manufactures, and markets proprietary biological testing technologies with applications throughout the diagnostic and life sciences industries. The company’s xMAP® multiplex solutions include an open-architecture, multi-analyte technology platform that delivers fast, accurate, and cost-effective bioassay results to markets as diverse as pharmaceutical drug discovery, clinical diagnostics, and biomedical research, including the genomics and proteomics markets. The company’s xMAP Technology is sold worldwide and is already in use in leading clinical laboratories, as well as major pharmaceutical, diagnostic, and biotechnology companies. Further information on Luminex Corporation or xMAP Technology can be obtained at www.luminexcorp.com.
About Life Technologies (www.lifetechnologies.com)
Life Technologies Corporation (NASDAQ: LIFE) is a global biotechnology company dedicated to improving the human condition. Our systems, consumables and services enable researchers to accelerate scientific and medical advancements that make life even better. Life Technologies customers do their work across the biological spectrum, working to advance the fields of discovery and translational research, molecular medicine, stem cell-based therapies, food safety and animal health, and 21st century forensics. The company manufactures both molecular diagnostic and research use only products. Life Technologies’ industry-leading brands are found in nearly every life sciences lab in the world and include innovative instrument systems under the Applied Biosystems and Ion Torrent names, as well as, the broadest range of reagents with its Invitrogen, GIBCO, Ambion, Molecular Probes and TaqMan® products. Life Technologies had sales of $3.6 billion in 2010, has a workforce of approximately 11,000 people, has a presence in approximately 160 countries, and possesses one of the largest intellectual property estates in the life sciences industry, with approximately 3,900 patents and exclusive licenses. For more information on how we are making a difference, please visit our website: http://www.lifetechnologies.com.
Life Technologies’ Safe Harbor Statement
This press release includes forward-looking statements about our anticipated results that involve risks and uncertainties. Some of the information contained in this press release, including, but not limited to, statements as to industry trends and Life Technologies’ plans, objectives, expectations and strategy for its business, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Any statements that are not statements of historical fact are forward-looking statements. When used, the words “believe,” “plan,” “intend,” “anticipate,” “target,” “estimate,” “expect” and the like, and/or future tense or conditional constructions (“will,” “may,” “could,” “should,” etc.), or similar expressions, identify certain of these forward-looking statements. Important factors which could cause actual results to differ materially from those in the forward-looking statements are detailed in filings made by Life Technologies with the Securities and Exchange Commission. Life Technologies undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances.
Contacts:
Luminex Investor Contact:
Matthew Scalo, 512.219.8020
Sr. Director Investor Relations
mscalo@luminexcorp.com
Luminex Media Contact:
Mimi Torrington, 512.219.8020
Director of Marketing Communications
mtorrington@luminexcorp.com
Aaron DeLucia, 512.241.2249
aaron.delucia@porternovelli.com
Life Technologies Media Contact:
Mauricio Minotta, 760-929-2456
Sr. Manager, Corporate Communications
Mauricio.minotta@lifetech.com
SOURCE Luminex Corporation; Life Technologies Corporation
